The product is disappearing into reorder rhythm: revenue is shifting from won-each-time to arriving-on-its-own, and the
The model's full reasoning — Q1 2024 call → NOWe need to determine if management describes a growing share of revenue that arrives without a new selling event, and that this share has recently and visibly grown as a proportion of the business, with grounding in observed current behavior. Let's examine the transcript. Management discusses various products. Key points: - NanoKnife: disposable revenue grew 34.5% year-over-year. They talk about growth in both U.S. and international. This is consumable pull-through from installed base? They mention "disposable revenue" which is recurring from procedures. But is there a statement that this is a growing share of total revenue? They mention Med Tech segment growth, but not specifically that self-arriving revenue is a larger proportion. - Auryon: They talk about placements and utilization. They mention shifting lasers to higher volume users, driving utilization. That suggests revenue from consumables (laser catheters) from installed base. But again, is there a statement about the proportion growing? - They mention "Med Tech platforms comprised 33% of total revenue compared to 31% a year ago." That's a shift, but that's not specifically about self-arriving revenue. - They talk about "backlog" but that's not relevant. - They mention "repeat" or "reorder" behavior? Not explicitly. - They talk about "installed base" for Auryon: "we finished the quarter with right around 415 total lasers in the field, that's about 10 new net from the end of the year, but then also a significant number of lasers that we've been shifting from maybe lower performing customers to finding some of those higher-performing customers." That suggests they are focusing on utilization from existing base, but not explicitly saying that revenue from consumables is a growing share. - For NanoKnife, they talk about disposable revenue growth, but not about it being a larger share of total revenue. - They mention "Med Tech gross margins" etc.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
DUOT · Q4 2023 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, through reorders, renewals, etc., and that this has recently and visibly grown as a ...
QTRX · Q3 2023 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, like through reorders, consumables, etc., and that this share has recently grown.
CYBR · Q3 2021 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, like through renewals, and that this has recently grown as a proportion.